Annual report
4503.TEDINET S100SMI3
Period2022-04-01 → 2023-03-31
Filed2024-01-16
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amends S100R0I6. Amended by S100SMT5 (2024-01-16).
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.52T | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.30T | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥1.25T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.30T | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.31T | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥133.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥155.7bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥132.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥156.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥145.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥245.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥249.0bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥98.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥124.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥120.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥195.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥222.3bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥98.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥124.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥2.46T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.33T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.27T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.32T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.90T | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥948.6bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥872.1bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.51T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.46T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.39T | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.51T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.46T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.39T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.29T | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.26T | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥376.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥316.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥326.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥318.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥311.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥327.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥257.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥306.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥222.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥258.6bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥84.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥62.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥389.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥41.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥195.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥216.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥229.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥181.1bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥233.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥54.24 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥67.08 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥64.93 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥104.15 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥115.05 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥54.09 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.05 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥64.9 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥104.08 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥114.94 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥839.26 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥799.26 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥748.03 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥694.03 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥667.29 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 61.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.0% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 55.7% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 6.7% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 15.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 14,484 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 14,522 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 15,455 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 15,883 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 16,243 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥613.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥542.6bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥545.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥600.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥607.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥130.6bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥105.9bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥338.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥270.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥223.4bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥293.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥209.7bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥348.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥254.1bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥314.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥225.1bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥193.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥240.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥178.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.49T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.39T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.35T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.33T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.23T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥466.1bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥514.9bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.02T | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥873.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥787.7bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥671.6bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥565.6bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥217.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥184.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥172.64 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.69 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.95 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.26 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.49 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥172.57 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥121.63 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥103.89 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥128.17 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.4 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥60 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥568.97 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥477.81 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥424.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥361.08 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥299.34 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 33.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 26.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.4% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,809,663,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,835,852,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,861,787,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,861,787,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,979,823,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,867 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,943 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,647 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,560 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 5,034 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 14484 pure |
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 4867 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,666
| Item | Context | Value | Unit |
|---|---|---|---|
| Other components of intangible assets accumulated amortization and impairment losses IFRS | Prior1YearInstant | -42601000000 | JPY |
| Intangible assets accumulated amortization and impairment losses IFRS | Prior1YearInstant | -370512000000 | JPY |
| Technology related to research and manufacturing IFRS | Prior1YearInstant | 138614000000 | JPY |
| In process research and development IFRS | Prior1YearInstant | 300835000000 | JPY |
| Marketing rights IFRS | Prior1YearInstant | 124286000000 | JPY |
| Other components of intangible assets IFRS | Prior1YearInstant | 59696000000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 623431000000 | JPY |
| Technology related to research and manufacturing acquisition cost IFRS | CurrentYearInstant | 195221000000 | JPY |
| In process research and development acquisition cost IFRS | CurrentYearInstant | 468935000000 | JPY |
| Marketing rights acquisition cost IFRS | CurrentYearInstant | 237857000000 | JPY |
| Other components of intangible assets acquisition cost IFRS | CurrentYearInstant | 128714000000 | JPY |
| Intangible assets acquisition cost IFRS | CurrentYearInstant | 1030727000000 | JPY |
| Technology related to research and manufacturing accumulated amortization and impairment losses IFRS | CurrentYearInstant | -46295000000 | JPY |
| In process research and development accumulated amortization and impairment losses IFRS | CurrentYearInstant | -177841000000 | JPY |
| Marketing rights accumulated amortization and impairment losses IFRS | CurrentYearInstant | -173585000000 | JPY |
| Other components of intangible assets accumulated amortization and impairment losses IFRS | CurrentYearInstant | -70509000000 | JPY |
| Intangible assets accumulated amortization and impairment losses IFRS | CurrentYearInstant | -468230000000 | JPY |
| Technology related to research and manufacturing IFRS | CurrentYearInstant | 148925000000 | JPY |
| In process research and development IFRS | CurrentYearInstant | 291094000000 | JPY |
| Marketing rights IFRS | CurrentYearInstant | 64272000000 | JPY |
| Other components of intangible assets IFRS | CurrentYearInstant | 58205000000 | JPY |
| Intangible assets IFRS | CurrentYearInstant | 562496000000 | JPY |
| Raw materials ca IFRS | Prior1YearInstant | 61040000000 | JPY |
| Raw materials ca IFRS | CurrentYearInstant | 65667000000 | JPY |
| Work in process ca IFRS | Prior1YearInstant | 30517000000 | JPY |
| Work in process ca IFRS | CurrentYearInstant | 45397000000 | JPY |
| Merchandise and finished goods ca IFRS | Prior1YearInstant | 61515000000 | JPY |
| Merchandise and finished goods ca IFRS | CurrentYearInstant | 63322000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 153072000000 | JPY |
| Inventories ca IFRS | CurrentYearInstant | 174386000000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 184045000000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 216974000000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 146239000000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 148687000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant_NonConsolidatedMember | 28458000000 | JPY |
| Merchandise and finished goods | CurrentYearInstant_NonConsolidatedMember | 50747000000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | － | JPY |
| Work in process | CurrentYearInstant_NonConsolidatedMember | 1787000000 | JPY |
| Raw materials | Prior1YearInstant_NonConsolidatedMember | 22024000000 | JPY |
| Raw materials | CurrentYearInstant_NonConsolidatedMember | 27598000000 | JPY |
| Other ca | Prior1YearInstant_NonConsolidatedMember | 65500000000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 138495000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant_NonConsolidatedMember | -51000000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant_NonConsolidatedMember | -38000000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 446215000000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 584250000000 | JPY |
| Buildings net | Prior1YearInstant_NonConsolidatedMember | 38758000000 | JPY |
| Buildings net | CurrentYearInstant_NonConsolidatedMember | 70336000000 | JPY |
| Structures net | Prior1YearInstant_NonConsolidatedMember | 1542000000 | JPY |
| Structures net | CurrentYearInstant_NonConsolidatedMember | 4815000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |